Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Operating Income: 2021-2023

Historic Operating Income for Cullinan Therapeutics (CGEM) over the last 3 years, with Dec 2023 value amounting to -$45.5 million.

  • Cullinan Therapeutics' Operating Income fell 39.49% to -$45.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$191.1 million, marking a year-over-year decrease of 232.11%. This contributed to the annual value of -$196.9 million for FY2024, which is 3.05% down from last year.
  • Per Cullinan Therapeutics' latest filing, its Operating Income stood at -$45.5 million for Q4 2023, which was down 0.53% from -$45.2 million recorded in Q3 2023.
  • Over the past 5 years, Cullinan Therapeutics' Operating Income peaked at $239.7 million during Q2 2022, and registered a low of -$62.8 million during Q1 2023.
  • For the 3-year period, Cullinan Therapeutics' Operating Income averaged around -$9.5 million, with its median value being -$32.6 million (2022).
  • The largest annual percentage gain for Cullinan Therapeutics' Operating Income in the last 5 years was 1,543.50% (2022), contrasted with its biggest fall of 2,480.25% (2022).
  • Over the past 3 years, Cullinan Therapeutics' Operating Income (Quarterly) stood at -$34.3 million in 2021, then rose by 5.06% to -$32.6 million in 2022, then plummeted by 39.49% to -$45.5 million in 2023.
  • Its Operating Income stands at -$45.5 million for Q4 2023, versus -$45.2 million for Q3 2023 and -$37.6 million for Q2 2023.